Commvault Systems Inc vs Johnson & Johnson — how do they compare? Commvault Systems Inc trades at $148.1 (market cap $6.15B), while Johnson & Johnson trades at $247.74 (market cap $611.07B). The key difference: Johnson & Johnson is far larger — about 99.4× Commvault Systems Inc's market cap, and Johnson & Johnson pays a 2.11% dividend while Commvault Systems Inc pays none. Which is the better fit depends on your goals.
| CVLT | JNJ | |
|---|---|---|
Market Cap | $6.15B | $611.07B |
Sector | Technology | Health |
52-Week High | $195.41 | $267.24 |
52-Week Low | $75.18 | $162.98 |
Enterprise Value | $6.17B | $644.01B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.11% |
Signals from Pluang's Aura AI — not financial advice
Commvault (CVLT) trades at $148.65, down 1.28% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.28 exceeding the $1.09 estimate, though Q3 2025 missed expectations. Revenue reached $995.62 million in 2025, with a net income margin of 5.97%. However, valuation ratios are elevated, including a P/E of 94.03 and P/B of 821.14, indicating high growth expectations. Recent news highlights multiple class-action lawsuits with a July 17, 2026 deadline, adding legal overhangs.
The outlook for CVLT is mixed, with solid profitability and analyst buy ratings (54.55% consensus) supporting upside to the $155.00 high target, but risks from the lawsuits and rich valuations could pressure the stock. Investors should weigh robust cash flow growth in 2026 against potential legal and competitive headwinds in the data protection sector.
Johnson & Johnson (JNJ) trades at $257.77, up 0.31% with a bullish technical signal and strong institutional support. The stock shows robust fundamentals with 2025 revenue of $94.19B, net income margin of 21.83%, and consistent earnings beats. Recent dividend declaration of $1.34 and positive analyst coverage with 52.5% buy ratings reinforce confidence. The current price sits near pivot point resistance at $258, with technical indicators showing bullish momentum from moving averages.
JNJ presents a compelling long-term investment with stable cash flows, strong profitability metrics, and defensive healthcare positioning. Upside potential exists toward the $281 consensus price target, though risks include rising debt-to-asset ratio (24.06% in 2025) and patent expiration headwinds. The stock's 60+ year dividend growth history provides income stability amid market volatility.
Trailing returns across standard periods
Latest headlines on both assets
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →